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Abstract
Background: Serum markers of inflammation are candidate biomarkers in multiple sclerosis (MS). ω-3 fatty acids
are suggested to have anti-inflammatory properties that might be beneficial in MS. We aimed to explore the
relationship between serum levels of inflammation markers and MRI activity in patients with relapsing remitting MS,
as well as the effect of ω-3 fatty acids on these markers.
Methods: We performed a prospective cohort study in 85 relapsing remitting MS patients who participated in a
randomized clinical trial of ω-3 fatty acids versus placebo (the OFAMS study). During a period of 24 months 12
repeated magnetic resonance imaging (MRI) scans and nine serum samples were obtained. We measured 10
inflammation markers, including general down-stream markers of inflammation, specific markers of up-stream
inflammatory pathways, endothelial action, and matrix regulation.
Results: After Bonferroni correction, increasing serum levels of CXCL16 and osteoprotegerin were associated with
low odds ratio for simultaneous MRI activity, whereas a positive association was observed for matrix
metalloproteinase (MMP) 9. CXCL16 were also associated with low MRI activity the next month, but this was not
significant after Bonferroni correction. In agreement with previously reported MRI and clinical results, ω-3 fatty acid
treatment did not induce any change in the inflammation markers.
Conclusions: Serum levels of CXCL16, MMP-9, and osteoprotegerin reflect disease activity in MS, but are not
affected by ω-3 fatty acid treatment. CXCL16 could be a novel biomarker and potential predictor of disease activity in
MS.
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Introduction
The inflammatory response in multiple sclerosis (MS)
involves a complex interaction between T cells, B cells,
macrophages, dendritic cells, and endothelial cells. Whereas
several inflammatory cytokines and growth factors have been
suggested as potential mediators [1], their regulation and
relative importance are not clear. Moreover, the
immunopathogenesis of MS also involves matrix remodeling,
including activation of various matrix degrading enzymes such
as matrix metalloproteinases (MMPs) [2]. In addition,
inflammatory mediators could also mediate neuroprotection
and repair [3,4].
Current MS treatments have limited effect and
complementary treatments, including ω-3 fatty acids (FA), are
used by many patients [5]. However, although ω-3 FA are
suggested to have anti-inflammatory properties [6–8], the
evidence underpinning their ability to modulate inflammation in
MS is largely unknown. We have recently reported that the ω-3
FA in Multiple Sclerosis (OFAMS) study, a randomized clinical
trial of 1350 mg eicosapentaenoic acid (EPA) and 850 mg
docosahexaenoic acid (DHA) daily versus placebo (corn oil),
failed to show any effect on disease activity as assessed by
magnetic resonance imaging (MRI) [9]. Whether this reflects an
inability to modulate inflammation was not examined in the
primary report.
The aim of this sub-study was to assess (i) the association
between inflammatory markers and simultaneous or
subsequent MRI activity in the OFAMS study population, and
(ii) whether treatment with ω-3 fatty acids affects serum
markers of inflammation. We examined general down-stream
markers of inflammation including pentraxin 3 (PTX3),
osteopontin (OPN), soluble tumor necrosis factor receptor type
1 (sTNF-R1), osteoprotegerin (OPG) and interleukin (IL)-1
receptor antagonist (IL-1RA), more specific markers of up-
stream inflammatory pathways such as CXCL16, CCL21 and
transforming growth factor (TGF) β, markers of endothelial
action including activated leukocyte cell adhesion molecule
(ALCAM) and MMP-9. All together, these markers will reflect
inflammatory pathways (e.g., PTX3, OPG, sTNF-R1, IL-1Ra
and CXCL16), the interaction between leukocytes and
endothelial cells (e.g., PTX3, ALCAM, CXCL16 and CCL21)
and extracellular matrix remodeling (e.g., OPN, OPG, TGFβ
and MMP-9), all processes with relevance for the pathogenesis
of MS.
Materials and Methods
Ethic statement
The study was approved by the Regional Committee for
Medical and Health Research Ethics in Western Norway. All
participants gave written informed consent.
Study population and design
The OFAMS study was a randomized double-blind, placebo-
controlled trial that included 92 Norwegian patients with
relapsing remitting (RR) MS according to the McDonald criteria
[9]. The inclusion criteria were age 18-55 years, Expanded
Disability Status Scale (EDSS) score ≤5, and ≥1 relapse or
new T1-weighted gadolinium enhancing (T1Gd+) or T2-
weighted (T2) MRI lesion the last year. None of the patients
used immunomodulatory drugs at inclusion. At baseline the
patients were randomized to receive either Triomar™ capsules
(Pronova Biocare, Sandefjord, Norway) containing 1350 mg of
EPA and 850 mg of DHA or placebo (corn oil). At month six all
patients started subcutaneous interferon β-1a (IFNβ) injections
thrice weekly. Serum was collected at baseline and after 1, 3,
6, 7, 9, 12, 18 and 24 months. MRI was performed at baseline
and monthly during months 1 to 9, and after 12 and 24 months.
Measurement of inflammation markers
Serum samples were collected by venipuncture and stored at
-80°C until analysis. The concentrations of OPG, sTNF-R1, the
chemokines CXCL16 and CCL21, TGFβ1, PTX3, MMP-9,
IL-1RA, OPN, and ALCAM were measured by enzyme
immunoassay (EIA) obtained from R&D systems (Minneapolis,
MN, USA). The analyses were performed simultaneously for all
samples from each patient. For each marker consecutive
samples from each patient were analysed in neighbouring wells
on the same plate. The lab technicians were blinded for
treatment as well as MRI activity. The intra- and inter-assay
coefficient of variation were <10% for all EIAs.
HLA-DRB1 typing
The HLA-DRB1 status was determined by DNA sequencing
using SeCore Loc DRB1 SEQ kit (Invitrogen, Carlsbad, Ca,
USA) at the Department of Immunology, Oslo University
Hospital, Oslo, Norway.
MRI measurements
As previously described [9], MRI was performed according to
a standardised protocol comprising T2-weighted and T1-
weighted Gd+ scans using a standard head coil with a 1.5 Tesla
MRI Unit. Blinded assessments of T1Gd+ lesions, T2 lesions,
and combined unique activity (CUA; the sum of T1Gd+ lesions
and new or enlarging T2 lesions) were conducted by two
experienced neuroradiologists.
Missing values
Due to restricted amount of serum, not all inflammation
markers could be measured at all time points. All inflammation
markers were, however, measured in at least three serum
samples from each patient, except three patients with none or
one measurements of IL-1Ra or ALCAM. Fourteen (2.7%) and
nine (2.0%) MRI scans were missing during study months 1-6
and 7-24, respectively. The number of patients, MRI scans and
measurements of inflammatory markers contributing to each
analysis are provided in the results. Body mass index (BMI)
was missing for two patients. Missing values were not
replaced.
Statistical analyses
Mean values with standard deviations (SD) are used to
describe clinical data and the inflammation markers. The MRI
outcomes were skewed towards none or one lesion and were
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therefore dichotomised as present or absent. Since most
inflammation markers were skewed, logarithmically
transformed values were used in the statistical analyses. There
was a considerable intra-individual variation in logarithmically
transformed inflammation markers as measured by the intra-
class correlation coefficient (ICC). The association between the
inflammation markers and simultaneous or subsequent (one
study month later) MRI activity was therefore assessed by a
logistic regression model for hierarchical data. The SAS
GLIMMIX procedure was used to fit a model with random
intercepts for patients and fixed effects for inflammation
markers. Only paired measurements of inflammation markers
and MRI outcomes were included in the regression model. Due
to logarithmic transformation of inflammation markers, odds
ratios (OR) for MRI activity associated with each 1 SD increase
in inflammation markers were estimated. The impact of gender,
age, BMI, and HLA-DRB1*15 status on MRI activity and
inflammation markers was assessed by t-test for regression
coefficients in a multivariate regression model. Some
logarithmically transformed inflammation markers were
different in the ω-3 FA and the placebo group at baseline. The
consecutive values were therefore divided by corresponding
baseline measurements (all on logarithmic scale) before
assessing the effect of ω-3 FA treatment. Consequently, this
effect could not be examined in patients lacking baseline value
for the particular marker. Because of substantial intra-individual
variation, the linear mixed model approach was chosen in
favour of independent samples t-test for assessing the mean
differences in inflammation markers between the ω-3 FA-
treated and placebo-treated groups. The homoscedasticity in
inflammation markers at different study months was assessed
by Levene’s test (SAS GLM procedure). The linear model with
random intercepts for patients and indicator variable identifying
group-belonging as fixed effect was fitted (SAS MIXED
procedure). The adjustment for heteroscedastic variances was
introduced into the linear mixed models for inflammation
markers, where Levene’s test was significant (highlighted by an
asterisk in the table reporting the results). The statistical
analyses were conducted using SPSS version 18.0 and SAS
version 9.2. Due to multiple testing, Bonferroni correction was
performed for the association between MRI activity and
inflammation markers during the whole study period, which was
considered the main analyses. Assuming 30 tests (10
inflammation markers and three MRI outcomes), p values <
0.0017 were considered significant in this analysis.
Results
Of the 92 patients included in the OFAMS study, sufficient
serum or MRI scans were missing from seven. Thus, 85
patients, 55 (65%) women and 30 (35%) men, age 38.7 (8.1)
years, BMI 25.8 (4.3), disease duration 1.9 (3.1) years, and
EDSS score at baseline 1.9 (0.8) were included in this study.
Mean levels of the inflammation markers at baseline and during
different phases of the study are shown in Table 1. The
concentrations and the proportion of positive MRI scans at
each time point throughout the study are given in Table S1.
The ICC for log-transformed inflammation markers varied
between 0.43 (MMP-9) and 0.77 (CXCL16), implying that
between 23% and 57% of the total variation was intra-
individual. The mean concentration of most of the inflammation
markers before IFNβ treatment differed from that recorded
during IFNβ treatment (Table 1). Gender, age, BMI, or the
presence of HLA-DRB1*15 were not associated with any of the
markers.
The association between inflammatory markers and
disease activity as assessed by MRI
To assess whether the inflammation markers reflect disease
activity, a logistic regression model for hierarchical data was
fitted to estimate the OR for simultaneous MRI activity
associated with 1 SD increase in each inflammation marker
(Table 2). After Bonferroni correction, increasing
concentrations of OPG were associated with lower OR for new
T1Gd+ and T2 lesions and CUA (i.e., the combination of the
two other MR parameters), and increasing levels of CXCL16
were associated with lower OR for new T1Gd+ lesions and
CUA. In contrast to the inverse associations with these
markers, increasing concentrations of MMP-9 were associated
with more new T1Gd+ lesions. The temporal relationship
between MRI activity and CXCL16, OPG and MMP-9 is shown
in Figure 1. Less pronounced inverse associations were
recorded between MRI activity and IL-1Ra and sTNFR1, and
positive associations with TGFβ, but these associations were
not significant after Bonferroni correction. None of the
associations were influenced by adjusting for gender, age, BMI,
or the presence of HLA-DRB1*15 (data not shown).
As shown in Table 1 and Figure 1, the MRI outcomes and
also most inflammation markers differed between before and
during IFNβ treatment. OR for simultaneous MRI activity
associated with each inflammation marker before (month 0-6)
and during (month 7-24) IFNβ treatment is shown in Table 3. A
clear pattern was observed for OPG which was inversely
associated with all MRI outcomes during IFNβ treatment,
whereas no associations were recorded before IFNβ treatment.
PTX3 was positively associated with new T2 lesions and CUA
before, but not during IFNβ treatment.
To assess whether markers of systemic inflammation also
predict disease activity, we estimated the relationship between
1 SD increase in each marker and MRI activity one month later
(Table 4). The association between CXCL16 and subsequent
CUA was equal to that recorded for simultaneous CUA,
whereas the ORs for new T1Gd+ and T2 lesions were
somewhat higher but in the same order of magnitude as for
simultaneous disease activity. Except a weak association
between OPG and new T1Gd+ lesions the next month, none of
the other inflammation markers were associated with MRI
activity the following month. None of the associations with
subsequent MRI activity reached a significance level of 0.0017,
although the association between CXCL16 and CUA was close
(p = 0.0021).
The effect of ω-3 FA treatment on inflammatory
markers
We have recently reported that the treatment with EPA and
DHA had no influence on disease MRI activity in these patients
CXCL16 Reflects Disease Activity in MS
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Table 1. Concentrations and intra-class correlation coefficients (ICC) of inflammation markers.
Inflammation marker Baseline Whole study period Omega-3 Placebo No IFB IFB p-value5
 N1 Mean (SD) n3 Mean (SD4) ICC2 n3 Mean (SD4) n3 Mean (SD4) n3 Mean (SD4) n3 Mean (SD4)  
PTX3 (ng/ml) 80 1255 725 1164 67.9 376 1186 349 1141 327 1143 398 1182 <0.001
  (1150)  (723)   (811)  (614)  (852)  (596)  
sTNF-R1 (pg/ml) 81 920 733 980 72.8 384 981 349 979 331 919 402 1030 <0.001
  (254)  (272)   (276)  (268)  (256)  (274)  
CXCL16 (pg/ml) 81 1262 728 1328 76.6 379 1199 349 1468 331 1218 397 1419 <0.001
  (772)  (634)   (379)  (804)  (662)  (595)  
MMP-9 (pg/ml) 81 836 734 585 43.4 384 481 350 700 331 728 403 468 <0.001*
  (1239)  (807)   (404)  (1078)  (937)  (660)  
CCL21 (pg/ml) 80 291 734 328 70.9 384 298 350 361 330 299 404 352 <0.001
  (139)  (161)   (127)  (186)  (142)  (172)  
IL-1Ra (pg/ml) 77 134 718 183 76.3 370 113 348 258 324 130 394 227 <0.001
  (350)  (629)   (230)  (866)  (393)  (768)  
OPN (ng/ml) 73 7.6 724 9.9 53.2 381 10.4 343 9.3 322 7.9 402 11.4 <0.001*
  (3.9)  (6.0)   (6.2)  (5.7)  (4.9)  (6.3)  
OPG (pg/ml) 73 1052 723 1141 60.7 379 1212 344 1062 322 1050 401 1214 <0.001
  (360)  (413)   (490)  (288)  (425)  (389)  
TGFβ1 (ng/ml) 71 21.4 722 20 45.9 379 21.0 343 19.3 320 20.7 402 19.8 0.062
  (8.1)  (7)   (8.1)  (6.4)  (7.5)  (7.3)  
ALCAM (ng/ml) 69 160 683 171 56.8 357 163 326 179 310 170 373 171 0.439
  (81)  (74)   (69)  (78)  (74)  (74)  
1 Number of patients with a baseline measurement; 2 ICC (%) is calculated for logarithmically transformed data with baseline measurements included; 3 Number of
measurements in the analyses; 4 Calculated ignoring clustering; 5 p-value from the model from mixed model with random intercepts and heteroscedastic residuals where
relevant (irrelevant indicated with *) for logarithmically transformed measurements
doi: 10.1371/journal.pone.0075021.t001
Figure 1.  MRI activity and mean concentrations (positive SD) of inflammation markers significantly associated with MRI
outcomes throughout the study.  All available observations at each time point are included (see Table S1 for numbers). All T1Gd+
lesions are shown at month 0 (baseline). Abbreviations: CXCL16: Chemokine (C-X-C motif) ligand 16, OPG: osteoprotegerin,
MMP-9: matrix metalloproteinase 9, T1Gd+: gadolinium enhancing T1 MRI lesion, CUA: combined unique activity.
doi: 10.1371/journal.pone.0075021.g001
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[9]. The effect of ω-3 FA treatment on the inflammation
markers is shown in Table 5. As compared with placebo, ω-3
FA treatment did not induce any significant change in any of
the inflammation markers before or after initiation of IFNβ, or
during the whole study period.
Discussion
We have tested a broad panel of inflammation markers, of
which CXCL16 and OPG were inversely, and MMP-9 positively
associated with simultaneous MRI activity. Treatment with EPA
and DHA did not alter the serum levels of any of these
inflammation markers.
Several chemokines and chemokine receptors, including
CXCL8, CXCL13, CXCL12, CCL2, and CCL19 have been
suggested as possible biomarkers in MS [10–13]. In this study
CXCL16 stood out compared to the other markers as it
reflected simultaneous MRI activity and was also associated
with a trend for low subsequent MRI activity. CXCL16 is
expressed on the surface of antigen presenting cells where it
serves as a ligand for CXCR6 on T cells and natural killer T
Table 2. Odds ratios for simultaneous MRI activity for each
1 SD increase in each inflammation marker.
 Odds ratio (95% CI)
 p-value
Inflammation
marker N
Combined unique
activity New T2 lesions
New T1Gd+
lesions
 (n)    
PTX31  558 1.15 (0.90, 1.49) 1.17 (0.91, 1.49) 1.00 (0.78, 1.30)
 (638) 0.25 0.22 0.98
sTNF-R11  564 0.68 (0.53, 0.88) 0.75 (0.59, 0.96) 0.69 (0.54, 0.89)
 (645) 0.003 0.02 0.005
CXCL161  560 0.56 (0.42, 0.74) 0.66 (0.51, 0.86) 0.48 (0.35, 0.66)
 (641) <0.0013 0.002 <0.0013
MMP-91  565 1.37 (1.08, 1.73) 1.32 (1.04, 1.67) 1.50 (1.17, 1.91)
 (646) 0.009 0.02 0.0013
CCL211  566 0.83 (0.64, 1.06) 0.92 (0.72, 1.17) 0.74 (0.58, 0.95)
 (646) 0.13 0.49 0.02
IL-1Ra 2  555 0.77 (0.60, 0.99) 0.80 (0.62, 1.02) 0.70 (0.53, 0.91)
 (632) 0.04 0.07 0.007
OPN 2  563 0.89 (0.72, 1.12) 0.93 (0.74, 1.16) 0.82 (0.65, 1.03)
 (636) 0.323 0.507 0.084
OPG2  562 0.56 (0.43, 0.72) 0.61 (0.48, 0.79) 0.55 (0.42, 0.72)
 (635) <0.0013 <0.0013 <0.0013
TGFβ2  563 1.27 (0.99, 1.62) 1.16 (0.92, 1.47) 1.39 (1.07, 1.79)
 (634) 0.05 0.21 0.01
ALCAM2  535 0.98 (0.77, 1.25) 1.03 (0.81, 1.31) 1.05 (0.82, 1.34)
 (604) 0.85 0.82 0.70
N: Number of measurements included in the analysis of new T2 lesions and
combined unique activity; (n): Number of measurements included in the analysis of
new T1Gd+ lesions.
1 Analysed in 85 patients. 2 Analysed in 84 patients. 3 Significant after
Bonferroni correction.
doi: 10.1371/journal.pone.0075021.t002
cells. The expression of CXCL16 is induced by inflammatory
mediators including IFNγ and TNFα, and it can be shed into the
circulation as a soluble chemokine that activates CXCR6
expressing cells [14]. Both CXCL16 and CXCR6 are expressed
in the CNS, and protect against excitotoxic damage caused by
excessive glutamate exposure and oxygen and glucose
deprivation [15]. CXCL16 has also been shown to regulate T
cell homing to the CNS in experimental autoimmune
encephalomyelitis (EAE) [16], and it was recently shown in this
model that immature myeloid cells expressing CXCL16 redirect
CXCR3 + CXCR6+ and myelin-specific T cells from CNS to
lymph nodes [17]. To our knowledge, only one cross-sectional
study has previously analyzed CXCL16 levels in MS patients,
Table 4. Odds ratio for subsequent MRI activity for 1 SD
increase in each inflammation marker (MRI outcomes
lagged by one month).
  Odds ratio (95% CI) p-value
Inflammation
marker  
Combined unique
activity New T2 lesions
New T1Gd+
lesions
 N    
PTX31 393 1.09 (0.81, 1.47) 1.05 (0.80,1.39) 1.01 (0.75, 1.36)
  0.57 0.73 0.96
sTNF-R11 396 0.79 (0.58, 1.09) 0.81 (0.61,1.09) 0.78 (0.56, 1.07)
  0.15 0.17 0.12
CXCL161 395 0.65 (0.46, 0.93) 0.60 (0.43,0.83) 0.58 (0.40, 0.84)
  0.02 0.002 0.004
MMP-91 396 1.17 (0.87, 1.58) 1.20 (0.90,1.60) 1.14 (0.84, 1.54)
  0.31 0.21 0.41
CCL211 395 1.03 (0.75, 1.41) 0.94 (0.71,1.26) 0.83 (0.61, 1.13)
  0.85 0.70 0.23
IL-1Ra2 389 0.85 (0.62, 1.17) 0.86 (0.64,1.15) 0.88 (0.64, 1.21)
  0.32 0.30 0.42
OPN1 388 0.91 (0.68, 1.21) 0.88 (0.69,1.16) 0.93 (0.69, 1.25)
  0.51 0.37 0.61
OPG1 387 0.78 (0.57, 1.06) 0.85 (0.63,1.13) 0.68 (0.49, 0.95)
  0.11 0.25 0.02
TGFβ11 386 1.40 (1.00, 1.96) 1.17 (0.87,1.58) 1.20 (0.86, 1.67)
  0.05 0.31 0.28
ALCAM 3 369 0.90 (0.66, 1.23) 0.87 (0.66,1.17) 0.86 (0.63, 1.18)
  0.50 0.36 0.34
N: Number of measurements included in the analysis of new T2 lesions and
combined unique activity (n): Number of measurements included in the analysis of
new T1Gd+ lesions.
1 Analysed in 85 patients. 2 Analysed in 84 patients. 3 Analysed in 82 patients.
doi: 10.1371/journal.pone.0075021.t004
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reporting higher levels in CSF compared to serum and higher
levels in patients with MS and other inflammatory CNS
diseases compared to controls with non-inflammatory
neurological diseases [18]. Very recently CXCL16 was shown
to be expressed by macrophages and astrocytes in MS lesions
[19]. Our findings call for further studies in larger MS
populations with longer follow-up.
OPG and sTNF-R1 are members of the TNF receptor family,
while IL-1Ra is a receptor antagonist. These soluble receptors
and receptor antagonists may attenuate the pro-inflammatory
activity of their respective ligands, i.e., receptor activator of
nuclear factor kappaB ligand (RANKL), TNFα, and IL-1.
Injection of sTNF-R1 prevents EAE [20], whereas the role in
MS is less clear. IL-1Ra has been linked to MRI activity in MS
patients [21], but the study was too small to reach a firm
conclusion. Previous small studies have reported higher serum
OPG levels in MS patients compared to healthy controls [22],
and no difference in CSF OPG levels between patients with MS
and patients with non-inflammatory neurological diseases [23].
High serum levels of sTNF-R1 have been reported during [24]
and after [25] relapses in longitudinal studies, suggesting a
possible protective role in MS patients. A recent cross sectional
study was however negative [26]. Our findings that circulating
levels of OPG were inversely associated with MRI activity, and
the corresponding trends for sTNF-R1 and IL-1Ra, may
suggest a beneficial effects of these cytokine modulators in
MS, possibly mediated through their ability to block their
corresponding pathogenic ligands.
Unlike most of the examined markers, MMP-9 was positively
associated with MRI activity. MMP-9 is secreted by activated T
cells and microglia, and is involved in the digestion of
extracellular matrix and loss of blood brain barrier (BBB)
Table 3. Odds ratios for simultaneous MRI activity for each 1 SD increase in each inflammation marker before and during
interferon beta treatment.
Inflammation
marker Before interferon beta During interferon beta
 Odds ratio (95% CI) Odds ratio (95% CI)
 p-value p-value
 N1 (N2)
Combined unique
activity New NT2 lesions
New T1Gd+
lesions N3 (n)
Combined unique
activity New NT2 lesions
New T1Gd+
lesions
 (n)        
PTX3 242 (322) 1.48 (1.04, 2.13) 1.49 (1.08, 2.07) 1.16 (0.84, 1.59) 316 (85) 1.13 (0.80, 1.59) 1.03 (0.71, 1.49) 1.06 (0.71, 1.59)
 (84) 0.03 0.02 0.38  0.50 0.86 0.79
sTNF-R1 245 (326) 0.92 (0.64, 1.32) 1.01 (0.73, 1.40) 1.02 (0.71, 1.45) 319 (85) 0.75 (0.54, 1.04) 0.72 (0.50, 1.93) 0.70 (0.48, 1.02)
 (85) 0.64 0.95 0.93  0.08 0.07 0.07
CXCL16 245 (326) 0.88 (0.60, 1.28) 0.92 (0.67, 1.28) 0.75 (0.51, 1.10) 315 (84) 0.64 (0.45, 0.93) 0.63 (0.42, 0.93) 0.73 (0.48, 1.11)
 (85) 0.49 0.63 0.15  0.02 0.02 0.14
MMP-9 245 (326) 1.21 (0.84, 1.76) 1.23 (0.88, 1.73) 1.31 (0.91, 1.89) 320 (85) 1.02 (0.75, 1.39) 1.04 (0.75, 1.44) 1.03 (0.72, 1.47)
 (85) 0.31 0.22 0.15  0.90 0.81 0.87
CCL21 245 (325) 0.99 (0.68, 1.45) 1.13 (0.80, 1.59) 0.92 (0.66, 1.30) 321 (85) 0.98 (0.71, 1.36) 0.98 (0.69, 1.39) 0.94 (0.65, 1.35)
 (85) 0.98 0.50 0.65  0.90 0.92 0.72
IL-1Ra 242 (319) 0.96 (0.67, 1.39) 0.99 (0.71, 1.38) 1.02 (0.70, 1.47) 313 (84) 0.99 (0.72, 1.38) 0.95 (0.67, 1.35) 0.93 (0.64, 1.35)
 (84) 0.81 0.94 0.93  0.98 0.79 0.69
OPN 244 (317) 1.12 (0.79, 1.58) 1.10 (0.80, 1.51) 1.10 (0.78, 1.54) 319 (85) 1.28 (0.91, 1.79) 1.24 (0.87, 1.77) 1.25 (0.85, 1.85)
 (85) 0.51 0.56 0.58  0.16 0.24 0.25
OPG 244 (317) 0.93 (0.66, 1.32) 1.03 (0.75, 1.40) 1.00 (0.72, 1.40) 318 (85) 0.55 (0.38, 0.81) 0.47 (0.31, 0.71) 0.53 (0.35, 0.81)
 (85) 0.69 0.86 0.99  0.002 <0.001 0.004
TGFβ1 244 (315) 1.31 (0.92, 1.88) 1.18 (0.86, 1.63) 1.39 (0.96, 2.03) 319 (85) 1.10 (0.80, 1.51) 1.06 (0.76, 1.47) 1.04 (0.73, 1.48)
 (85) 0.14 0.29 0.08  0.57 0.75 0.87
ALCAM 236 (305) 1.04 (0.72, 1.49) 1.10 (0.80, 1.53) 1.20 (0.86, 1.66) 299 (81) 0.89 (0.64, 1.22) 0.90 (0.64, 1.27) 0.89 (0.61, 1.30)
 (82) 0.84 0.55 0.28  0.46 0.55 0.55
N1 (N2): Number of measurements included in the analysis of new T2 lesions and combined unique activity (new T1Gd+ lesions); N3: Number of measurements included in
the analysis; (n): Number of patients included in the analysis.
doi: 10.1371/journal.pone.0075021.t003
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integrity [27]. Thus the observed association with new T1Gd+
lesions fits well since such MRI activity is a marker of BBB
disruption. High levels of MMP-9 have previously been
reported to predict [28], and in agreement with our results
reflect [29], MRI activity in MS. A similar trend, although not
significant after Bonferroni correction, was recorded for TGFβ1.
It is believed that the main role of TGFβ1 is to maintain immune
tolerance and that it protects against inflammatory
demyelination [30,31]. However, recent studies suggest that
TGFβ1 could induce the generation of autoreactive Th17 cells
[32], a subset believed to promote disease activity in MS. In
addition, TGFβ1 signaling in the CNS has been shown to
precede paralysis in EAE, independent of Th17 cells [33].
Further studies are needed to clarify the role of this pluripotent
cytokine in MS.
For several markers, including CXCL16 and MMP-9,
analyzing the periods before and during IFNβ treatment yielded
weaker associations than those recorded for the whole study
period. This is compatible with the well known effect of IFNβ on
inflammation and MRI activity in MS, and the marked drop in
MRI activity and alteration in the concentrations of inflammation
markers between month 6 and 7 recorded in this study. It is
therefore likely that IFNβ had a substantial influence on our
results. However, as all patients received IFNβ from month 6,
we cannot draw definite conclusions on the effect of this
treatment. PTX3 was associated with high OR for MRI activity
before, but not during IFNβ treatment. Although this
observation concurs with a recent report on the association
between PTX3 and clinical disease activity [34], it may be an
incidental finding.
Our findings corroborate the inability of EPA and DHA to
modulate disease activity in MS [9]. Previous studies on the
effect of EPA and DHA on inflammatory markers in MS have
reached conflicting results. Gallai et al. reported a significant
decrease in the production of IL-1β, TNFα, IL-2, and IFN-γ in
peripheral blood mononuclear cells (PBMC) upon daily
supplementation with 3.0 g of EPA and 1.8 g of DHA [35],
whereas Weinstock-Guttman et al. found no effect on plasma
levels of a range of inflammatory markers of 1.98 g EPA and
1.32 g DHA compared to 6 g olive oil per day [36]. EPA and
DHA have also been demonstrated to reduce MMP-9 synthesis
in PBMC from MS patients [37]. Diverging results across
studies may be due to differences in doses, measurements in
PBMC versus serum/plasma, and in the content of the placebo
preparations [7]. The corn oil capsules used as placebo in the
OFAMS study contained 52% linoleic acid. Although most
studies have shown no effect of linoleic acid on systemic
inflammation markers [38], we cannot exclude an effect on
some of the inflammation markers.
The prospective design with repeated measurements of MRI
and inflammation markers in each patient allowed us to capture
both intra- and individual variation, and is a strength of this
study. The finding that up to 57% of the total variation of log
transformed levels of the inflammation markers was inter-
individual underscores the advantage of this approach.
Moreover, MRI scanning, collection of serum samples and
measurement of inflammation markers were standardized in all
patients. There are, however, also limitations to this study. The
restricted amount of serum did not allow measurement of all
inflammation markers in all patients, and the number of
patients may have been too low to detect minor effects of ω-3
Table 5. The effect of treatment with ω-3 fatty acids versus placebo on inflammation markers.
Inflammation marker  Before interferon beta During interferon beta Whole study period
  (Month 1-6) (Month 7-24) (Month 1-24)
 N N1, N21 Mean difference3 N1, N22 Mean difference3 N1, N21 Mean difference3
   (p-value2)  (p-value2)  (p-value2)
PTX3 (pg/ml) 80 128,107 75.0 (0.58) 200,175 -31.8 (0.83)* 328, 282 8.6 (0.93)*
sTNF-R1 (pg/ml) 81 131,107 21.2 (0.95) 207,175 15.9 (0.89)* 340, 282 17.3 (0.92)*
CXCL16 (pg/ml) 81 131,107 -267.6 (0.14) 204,175 -273.4 (0.61)* 335, 282 -273.6 (0.30)*
MMP-9 (ng/ml) 81 128,11 -275.1 (0.57) 205,18 -178.7 (0.20) 333, 290 -214.3 (0.33)*
CCL21 (pg/ml) 80 125,11 -65.4 (0.62) 203,18 -80.3 (0.39) 328, 290 -74.7 (0.42)*
IL-1Ra (pg/ml) 77 122,104 -93.0 (0.91)* 191,17 -227.6 (0.42)* 313, 274 -176.9 (0.50)*
OPN (ng/ml) 73 122,92 1.3 (0.08)* 196,152 1.5 (0.14) 318, 244 1.4 (0.13)*
OPG (pg/ml) 73 121,93 154.0 (0.86)* 195,152 151.2 (0.84)* 316, 245 151.7 (0.85)*
TGFβ1 (ng/ml) 71 118,91 2.6 (0.58)* 191,149 1.0 (0.91) 309, 240 1.6 (0.81)
ALCAM (ng/ml) 69 116,88 -13.9 (0.39)* 176,144 -14.4 (0.48) 292, 232 -14.1 (0.37)*
N: number of patients in the analysis.
1 N1 and N2 stand for sample size in ω-3 and placebo group, respectively; 2 p-value from the model from linear mixed model with random intercepts (* models with
adjustment for heteroscedastic residuals in different study months incorporated) for logarithmically transformed and baseline-adjusted measurements; 3 Mean difference
calculated on original scale with baseline measurements excluded.
doi: 10.1371/journal.pone.0075021.t005
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fatty acids on disease activity. Although IFNβ was always
injected in the evening and serum was always sampled in the
morning, the interval varied with up to 48 hours. This could
have affected the concentrations of some of the inflammation
markers that respond rapidly to IFNβ, and increased the
variability in the latter phase of the study. Any such effect
would, however, affect patients on ω-3FA and placebo equally.
Moreover, the SD of the inflammation markers was in the same
order of magnitude before and during IFNβ treatment, arguing
against any substantial effect. Another potential weakness is
that the interval between MRI scannings was markedly longer
at the end of the study. The MRI scans were distributed to
capture the high expected disease activity prior to IFNβ
treatment, and this could potentially influence the ratio between
new T1Gd+ lesions and new T2 lesions during different phases
of the study. There was, however, an even reduction in new
T1Gd+ and T2 lesions after the initiation of IFNβ, and this effect
is therefore likely to be minor.
Conclusions
In this longitudinal study serum levels of CXCL16, OPG and
MMP-9 reflect MRI activity in RRMS, suggesting that these
markers, in particular CXCL16 which also may predict disease
activity, could be potential markers of disease activity in MS.
Treatment with EPA and DHA did not affect the serum
concentrations of these or other inflammation markers. The
results obtained in this exploratory study need to be confirmed
and should encourage further studies, particularly on CXCL16
as a potential mediator and biomarker in MS.
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